Loading stock data…
IBRX
$7.58+0.15 (+2.02%)
Pre-Market$7.80+0.22 (+2.91%)· Last close May 5
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmunityBio, Inc. in the Healthcare sector is trading at $7.58. The stock is currently 39% below its 52-week high of $12.43, remaining 74.3% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why IBRX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.58
Potential Upside
5%
Whystock Fair Value$7.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$15.75+107.8%
Range$12.00 – $23.00
Fundamentals
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
73.35%
Volume
Today's trading volume
8.50M
Recent News
ImmunityBio FDA Warning And Lawsuits Test Anktiva Growth Story
ImmunityBio received an FDA warning letter criticizing promotional claims for its lead product Anktiva. Following the warning letter, multiple class action lawsuits were filed alleging misleading statements and securities fraud. The issues center on whether the company accurately represented Anktiva's profile in marketing and investor communications. For investors tracking ImmunityBio (NasdaqGS:IBRX), this comes at a time when interest in the stock has been high, with a current share price...
ImmunityBio to Report Q1 Earnings: What's in the Cards?
IBRX's Q1 outlook rides on Anktiva's surging uptake, with preliminary revenues showing triple-digit growth ahead of its earnings report later this month.
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now?
Is IBRX a good stock to buy? We came across a bullish thesis on ImmunityBio, Inc. on Investment Ideas by Antonio’s Substack by Antonio Linares. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.’s share was trading at $8.10 as of April 21st. ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and […]
ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026. Product revenue in the quarter was up 168% year over year to $44.2 million. The increase […]
What Makes ImmunityBio (IBRX) a New Buy Stock
ImmunityBio (IBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).